Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)

Name: Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)
Published: 2023
License: Public Domain

Sun Yat-sen University · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

hepatocellular-carcinoma

hepatocellular carcinoma, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)

Related documents